1. Treatment Options in Refractory Autoimmune Encephalitis

   • Alessandro Dinoto
   • Sergio Ferrari
   • Sara Mariotto

   Current Opinion Open access 02 August 2022 Pages: 919 - 931

   

2. New Oral Drugs for Migraine

   • Nazia Karsan
   • Peter J. Goadsby

   Review Article Open access 29 August 2022 Pages: 933 - 949

3. Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability

   • Ricardo Kienitz
   • Lara Kay
   • Laurent M. Willems

   Review Article Open access 16 August 2022 Pages: 951 - 975

   

4. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study

   • Jai Perumal
   • Roumen Balabanov
   • Robert J. Fox

   Original Research Article Open access 05 September 2022 Pages: 977 - 993

   

5. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy

   • Hannah A. Blair

   Adis Drug Evaluation 12 August 2022 Pages: 995 - 1005

6. Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval

   • Young-A Heo

   AdisInsight Report 30 July 2022 Pages: 1007 - 1013

   

7. Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

   • C. U. Correll
   • Ofer Agid
   • Oliver D. Howes

   Correction Open access 17 August 2022 Pages: 1015 - 1015

8. Correction to: Antiseizure Drugs and Movement Disorders

   • Michel Sáenz-Farret
   • Marina A. J. Tijssen
   • Alfonso Fasano

   Correction 17 August 2022 Pages: 1017 - 1018